EL CASO DE LA HEPATITIS C Y EL PROBLEMA GLOBAL DE ACCESO A LOS MEDICAMENTOS
By Ernesto Samper Pizano
“Los Estados partes en el presente Pacto reconocen el derecho de toda persona al disfrute del más alto nivel de salud física y mental”
(Pacto Internacional de Derechos económicos, sociales y culturales).
El 3 de marzo de 1989, en el aeropuerto de El Dorado de Bogotá, fui víctima de un atentado que casi me cuesta la vida. Por fortuna, recibí una atención rápida y eficaz en la clínica a donde fui trasladado. Lamentablemente, allí mismo, en medio de los afanes por salvarme, recibí una transfusión de sangre infectada por lo que entonces no se conocía como el virus de Hepatitis C, cuyo poder mortífero vino a ser descubierto y estudiado con posterioridad a mi atentado, cuando ya había dejado de ser presidente de Colombia. La eficaz persistencia de mi médico personal, el doctor Alonso Gómez Duque, me llevó a someterme entonces al calvario de un tratamiento para curar la enfermedad. Indagué, en primera instancia, qué tanto daño podía haber ocasionado en mi hígado. Los primeros exámenes de fibro-test, que miden a través de la sangre los niveles de fibrosidad hepática realizados en Francia, arrojaron, en un rango de 0 a 6, una cifra baja pero preocupante, entre 3 y 4, que aconsejaba, según el hepatólogo Víctor Hidrobo, un tratamiento inmediato. Tomé la decisión de hacerlo. Durante seis meses (que a mí me parecieron una eternidad) me apliqué una inyección semanal de interferón –una sustancia utilizada originalmente para la cura del cáncer– que acompañaba con seis pastillas diarias de rivarbirina para “fijar” el interferón, lo que convertía el tratamiento en una especie de quimioterapia ligera con muy molestos efectos colaterales. (more…)
This week the Prince Mahidol Awards conference will bring a global spotlight to the threat of emerging infectious diseases. The growing challenge of antimicrobial resistance (AMR) will feature prominently in these discussions. The timing could not be better, but we urgently need to see more action on the part of the UN Interagency Coordination Group on AMR and key intergovernmental agencies gathering in Bangkok. (more…)
The IP Negotiations Monitor summarizes the latest developments in multilateral and regional fora where intellectual property negotiations are taking place, and informs on upcoming meetings and events.
This update provides a snapshot of the activities of the Development, Innovation and Intellectual Property Programme during the month of December 2017.
Heading off Global Action on Access to Medicines in 2018
By Dr. Jorge Bermudez and Dr. Viroj Tangcharoensathien
At the dawn of 2018, political and health leaders must seize the growing momentum and opportunities to tackle the protracted challenges of access to medicines that undermine efforts to save lives and improve health as committed under the Agenda 2030 SDG by all UN member states. (more…)
There are several key social and environmental issues to watch out for in 2018 as they are close to reaching a tipping point, says this preview of the new year by the South Centre’s Executive Director Martin Khor. (more…)
South Centre Statement at the 27th Session of the World Intellectual Property Organization (WIPO) Standing Committee on the Law of Patents
As this year’s work in the WIPO substantive committees will end with the conclusion of the 27th session of the Standing Committee on the Law of Patents (SCP), we are reminded that next year will mark the tenth anniversary since the SCP had reconvened in 2008 with a focus on developing a balanced work programme on issues relating to the law of patents to also address development and public policy questions that arise in the context of the patent system. The work of the SCP, in this sense, is integral to advancing the WIPO Development Agenda.
As global health leaders warn that antibiotic resistance is leading to the end of modern medicine, the World Health Organization (WHO) issues guidelines to prohibit or restrict using antibiotics to feed animals reared for their meat. Urgent coordinated actions are needed to avoid the end of modern medicine. The author Martin Khor is the Executive Director of the South Centre. This article was also published by Inter Press Service (IPS) (more…)
This update provides a snapshot of the activities of the Development, Innovation and Intellectual Property Programme during the month of November 2017.
The International Debate on Generic Medicines of Biological Origin
The debate on generic medicines is not new. What makes it different today is that attacks levelled against biological products are couched in ever more “technical” and abstruse language that confuses even the World Health Organization (WHO).
